ライフサイエンスコーパス: differentiated thyroid carcinoma

1 f thyroid remnants after a thyroidectomy for differentiated thyroid carcinoma.

2 ergone total or near-total thyroidectomy for differentiated thyroid carcinoma.

3 most frequent sites of distant metastasis in differentiated thyroid carcinoma.

4 stunning on the efficacy of 131I therapy for differentiated thyroid carcinoma.

5 ion and radioiodine therapy in patients with differentiated thyroid carcinoma.

6 oncocytic carcinoma and 40% (2/5) in poorly differentiated thyroid carcinoma.

7 sed for treatment of suspected recurrence of differentiated thyroid carcinoma.

8 iodine-positive metastases in patients with differentiated thyroid carcinoma.

9 Hurthle's cell carcinoma, and 21% of poorly differentiated thyroid carcinomas.

10 nagement was standardized with that of other differentiated thyroid carcinomas.

11 oncocytic carcinoma (2/6 [33.0%]) or poorly differentiated thyroid carcinoma (1/5 [20.0%]).

12 Following thyroidectomy for differentiated thyroid carcinoma, 50 patients underwent

13 of 12 patients who received radioiodine for differentiated thyroid carcinoma also showed interstitia

14 ients with biochemical evidence of recurrent differentiated thyroid carcinoma and a tumor-negative ne

15 thyroidectomized patients with a history of differentiated thyroid carcinoma are presented who had n

16 Differentiated thyroid carcinomas are the most frequent

17 ts relationship to the widely prevalent well-differentiated thyroid carcinomas are unclear.

18 d on patients admitted for adjuvant RITh for differentiated thyroid carcinoma at the University Hospi

19 Patients with suspected recurrence from differentiated thyroid carcinoma, based on an increased

20 is frequently used after a thyroidectomy for differentiated thyroid carcinoma because it has been rep

21 otein galectin-3 is widely expressed in well-differentiated thyroid carcinomas, but not in normal thy

22 human papillary, Hurthle's cell, and poorly differentiated thyroid carcinoma by epigenetic and bioch

23 id tumors (for example, anaplastic or poorly differentiated thyroid carcinoma) carry several complex

24 In some patients with well-differentiated thyroid carcinoma, dosimetry is necessary

25 en found useful at stratifying patients with differentiated thyroid carcinoma (DTC) into prognostic r

26 The overall prognosis in pediatric differentiated thyroid carcinoma (DTC) is excellent.

27 tests and its active uptake by the thyroid, differentiated thyroid carcinoma (DTC) is the most serio

28 /CT in detecting recurrence or metastases in differentiated thyroid carcinoma (DTC) patients with ele

29 Differentiated thyroid carcinoma (DTC), as one of the ma

30 oma, including radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC), medullary thyroi

31 of cardiovascular mortality in patients with differentiated thyroid carcinoma (DTC).

32 evious reports, the majority of these poorly differentiated thyroid carcinomas express E-cadherin, bu

33 Two patients with advanced, well-differentiated thyroid carcinoma illustrate the need for

34 The well-differentiated thyroid carcinomas include papillary and

35 Iodine-131 scintigraphy for differentiated thyroid carcinoma is more sensitive and m

36 Adjuvant radioiodine therapy (RITh) for differentiated thyroid carcinoma is performed either wit

37 Achieving an optimal (131)I absorbed dose in differentiated thyroid carcinoma lesions is crucial for

38 on-frozen-section group, 3 (10%) showed well-differentiated thyroid carcinoma on permanent histology.

39 devascularized during thyroidectomy for well-differentiated thyroid carcinoma or benign disease shoul

40 o independent predictors of poor survival in differentiated thyroid carcinomas (P =.027 and P =.007,

41 nvasive and have well-defined foci of poorly differentiated thyroid carcinoma (PDTC).

42 consecutive post-thyroidectomy patients for differentiated thyroid carcinoma received a 185-MBq (5 m

43 f 18 years or older; total thyroidectomy for differentiated thyroid carcinoma; tumor-node-metastasis

44 f (131)I for treatment of patients with well-differentiated thyroid carcinoma; usual amounts vary wid

45 166 patients who underwent thyroidectomy for differentiated thyroid carcinoma was performed.

46 Among patients with differentiated thyroid carcinomas (WDC and PDC), 11 (55.

47 ent 131I therapy following thyroidectomy for differentiated thyroid carcinoma were enrolled, along wi

48 s retrospective study included patients with differentiated thyroid carcinoma who had undergone total

49 n progression-free survival in patients with differentiated thyroid carcinoma who were less than 21 y

50 hway may promote redifferentiation in poorly differentiated thyroid carcinomas with constitutive acti